Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

The purpose of this study was to apply the target-mediated drug disposition (TMDD) pharmacokinetic (PK) model to describe binding, internalization, and turnover of erythropoietin receptor (EPOR). This model allows one to determine from free drug (C) PK data not only parameters describing linear disposition of EPO such as the elimination rate constant (kel) and volume of distribution (Vc), but also the total receptor concentration (Rtot0), drug–receptor complex (RC) internalization rate constant (kint), as well as synthesis and degradation rate constants (ksyn and kdeg) for the receptor turnover. The previously published data on PK of recombinant EPO (rHuEPO) in humans and the results of EPOR binding studies were used for analysis. The estimated PK parameters were used to simulate time courses of free and bound EPOR after IV administration of clinically relevant rHuEPO doses. The estimates of kel = 0.106 h−1 and Vc = 0.032 l/kg are consistent with reported in the literature values of rHuEPO linear disposition parameters. The determined value of Rtot0 was 66.35 pM and the half-life for EPOR degradation was 8.8 h. Computer simulations showed a very rapid binding phase in the EPOR time profile followed by a decline to a nadir, and a subsequent return to the baseline. The nadir values decreased with increasing doses and resulted in the maximum values of the bound fractions of the total EPOR in the ranges 33–99%. At the baseline conditions, only 3.1% of EPOR were occupied. The saturation of EPOR was correlated with the time C remained above the KD level. In conclusion, the time courses of serum rHuEPO concentrations contain information about internalization and turnover of EPOR. Kinetics of EPOR can be utilized to determine the relationship between the pharmacologic effect and exposure to rHuEPO.

[1]  J. Malter,et al.  Zidovudine-induced blockade of the expression and function of the erythropoietin receptor. , 1992, Biochemical pharmacology.

[2]  J. Altin,et al.  Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes. , 2001, Biochimica et biophysica acta.

[3]  R. Ramakrishnan,et al.  Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Dose Administration in Cynomolgus Monkeys , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  R. Casale,et al.  Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. , 2000, European review for medical and pharmacological sciences.

[5]  W. Cheung,et al.  Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects* , 1998, Clinical pharmacology and therapeutics.

[6]  T. Quinn,et al.  Serum immunoreactive erythropoietin in HIV-infected patients. , 1989, JAMA.

[7]  V. Broudy,et al.  Erythropoietin receptor characteristics on primary human erythroid cells. , 1991, Blood.

[8]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[9]  R. Ramakrishnan,et al.  Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[10]  J. Adamson,et al.  Erythropoietin : molecular, cellular, and clinical biology , 1991 .

[11]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  W. Jusko,et al.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  J. Caro,et al.  Inappropriate increase in erythropoietin titers during chemotherapy , 1989, American journal of hematology.

[14]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[15]  P. Mayeux,et al.  Biology of erythropoietin. , 1998, Haematologica.

[16]  Ursula Klingmüller,et al.  Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.

[17]  G Levy,et al.  Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.

[18]  C. Halstenson,et al.  Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta , 1991, Clinical pharmacology and therapeutics.

[19]  J. Widness,et al.  Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  Sanford,et al.  Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. , 1987, The Journal of biological chemistry.

[21]  T. Arakawa,et al.  Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. , 1996, Biochemistry.

[22]  J. Widness,et al.  A Differential Pharmacokinetic Analysis of the Erythropoietin Receptor Population in Newborn and Adult Sheep , 2003, Journal of Pharmacology and Experimental Therapeutics.

[23]  C Revillard,et al.  [Clinical pharmacokinetics]. , 1976, Schweizerische medizinische Wochenschrift.

[24]  J. Glaspy,et al.  Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. , 2005, European journal of cancer.

[25]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[26]  J. Caro,et al.  Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men , 1990, Clinical pharmacology and therapeutics.

[27]  Y. Sugiyama,et al.  Receptor-Mediated Transport of Peptide Hormones and Its Importance in the Overall Hormone Disposition in the Body , 1989, Pharmaceutical Research.

[28]  Frédérique Verdier,et al.  Both proteasomes and lysosomes degrade the activated erythropoietin receptor. , 2005, Blood.

[29]  W. Jelkmann Erythropoietin: structure, control of production, and function. , 1992, Physiological reviews.

[30]  J. Fisher,et al.  Erythropoietin: Physiology and Pharmacology Update 2 , 2003, Experimental biology and medicine.

[31]  S. Tokura,et al.  Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction. , 1992, Arzneimittel-Forschung.